A new regime for paclitaxel in kaposi's sarcoma patients
CA 2189916 C · Owner: Gill, Parkash S. · Inventors: Gill, Parkash S.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
This invention provides for novel dose regimen of paclitaxel to treat Kaposi's sarcoma. Unlike current paclitaxel therapy protocols the claimed dosages are, lower yet surprisingly as effective in regression of KS tumors. In addition the lower, doses are accompanied with fewer incidents of undesired side effects. The effectiveness of low doses of paclitaxel as well as fewer and less debilitating side effects makes this, therapy protocol the first that can be used for long term and as maintenance therapy in the management of patients with Kaposi's sarcoma.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed November 8, 1996 and granted January 16, 2001. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended November 8, 2016.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by November 8, 2018.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.